Anti-inflammatory and autoimmune medicines treat conditions where the immune system is over-active or where chronic inflammation is the underlying driver of disease — including rheumatoid arthritis, lupus, inflammatory bowel disease (Crohn's and ulcerative colitis), psoriasis, severe atopic dermatitis, vasculitis, and solid-organ transplant rejection prevention. They range from broad-spectrum oral and injectable corticosteroids through targeted small-molecule disease-modifying antirheumatic drugs (DMARDs) to oral JAK inhibitors.
MedsBase stocks the full ladder of treatment, from short-course anti-inflammatory steroids (Wysolone, Predniheal, Medrol, Kenacort, Tricort) and gut-targeted budesonide (Budez CR) through hydrocortisone replacement therapy (Hisone), long-acting oral betamethasone (Betnesol), paediatric prednisolone syrup (Kidpred Syrup), and depot intramuscular/intra-articular triamcinolone (Kenacort Injection) to high-dose IV pulse methylprednisolone (Solu-Medrol). Conventional DMARDs include azathioprine (Azoran), leflunomide (Lefuheal), cyclosporine (Conimune ME); oral JAK inhibitors include baricitinib (Barinat) and tofacitinib (Tofe). Short-term NSAID analgesia is available with nimesulide (Nicip). Placentrex Injection remains a long-stocked option for chronic inflammatory dermatology and non-healing ulcer support.
These medicines require specialist supervision — rheumatology, gastroenterology, dermatology, transplant, or other appropriate specialty — with mandatory pre-treatment screening (latent TB, hepatitis B/C, baseline blood counts, and liver/kidney function) and ongoing laboratory monitoring throughout treatment. Use under qualified medical guidance.